The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-05-01 Epub Date: 2025-08-21 DOI:10.1080/14622416.2025.2547565

Eva González-Iglesias, Jesús Novalbos, Francisco Abad-Santos

{"title":"The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review.","authors":"Eva González-Iglesias, Jesús Novalbos, Francisco Abad-Santos","doi":"10.1080/14622416.2025.2547565","DOIUrl":null,"url":null,"abstract":"Introduction: Rosuvastatin has become a good choice in the statin group because it has shown greater efficacy in reducing lipid levels than other statins, allowing patients to reach their therapeutic goal more quickly. To date, research has shown a broad relationship between the kinetics and efficacy of this drug and the phenotype of two transporters, OATP1B1 and BCRP, encoded by SLCO1B1 and ABCG2 genes. However, there are many other genes whose variation may also affect the treatment.Objective: To conduct a systematic review including all information on the kinetics, measured by AUC and Cmax parameters; efficacy, by reduction in lipid levels and carotid intima-media thickness; and safety of rosuvastatin, by the occurrence of adverse events.Methods: A search of the published literature was conducted in PubMed using the term \"rosuvastatin AND pharmacogenetics\" (PROSPERO code: CRD420251041953).Results: A total of 37 articles were included, investigating 40 genes.Conclusions: The importance of ABCG2 in drug kinetics and efficacy and of SLCO1B1 in kinetics is confirmed, as is the possible association of CYP3A5 with efficacy and safety and of APOC1 with efficacy. There are also positive results for other genes that should be studied further to confirm their association with rosuvastatin.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"311-329"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2547565","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Rosuvastatin has become a good choice in the statin group because it has shown greater efficacy in reducing lipid levels than other statins, allowing patients to reach their therapeutic goal more quickly. To date, research has shown a broad relationship between the kinetics and efficacy of this drug and the phenotype of two transporters, OATP1B1 and BCRP, encoded by SLCO1B1 and ABCG2 genes. However, there are many other genes whose variation may also affect the treatment.

Objective: To conduct a systematic review including all information on the kinetics, measured by AUC and C_max parameters; efficacy, by reduction in lipid levels and carotid intima-media thickness; and safety of rosuvastatin, by the occurrence of adverse events.

Methods: A search of the published literature was conducted in PubMed using the term "rosuvastatin AND pharmacogenetics" (PROSPERO code: CRD420251041953).

Results: A total of 37 articles were included, investigating 40 genes.

Conclusions: The importance of ABCG2 in drug kinetics and efficacy and of SLCO1B1 in kinetics is confirmed, as is the possible association of CYP3A5 with efficacy and safety and of APOC1 with efficacy. There are also positive results for other genes that should be studied further to confirm their association with rosuvastatin.

查看原文本刊更多论文

瑞舒伐他汀的药物遗传学及其治疗意义：一项系统综述。

简介：瑞舒伐他汀在降低血脂水平方面比其他他汀类药物更有效，使患者更快达到治疗目标，因此成为他汀类药物组的良好选择。迄今为止，研究表明，该药物的动力学和疗效与SLCO1B1和ABCG2基因编码的两种转运体OATP1B1和BCRP的表型之间存在广泛的关系。然而，还有许多其他基因的变异也可能影响治疗。目的：通过AUC和Cmax参数测量，进行包括动力学所有信息的系统综述；通过降低脂质水平和颈动脉内膜-中膜厚度达到疗效；而瑞舒伐他汀的安全性，则由不良事件的发生而定。方法：检索PubMed上已发表的文献，检索词为“瑞舒伐他汀与药物遗传学”（PROSPERO代码：CRD420251041953）。结果：共纳入37篇文献，调查了40个基因。结论：ABCG2在药物动力学和疗效中的重要性、SLCO1B1在动力学中的重要性已被证实，CYP3A5与疗效和安全性、APOC1与疗效可能存在关联。其他基因也有阳性结果，需要进一步研究以确认它们与瑞舒伐他汀的关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.